Blebbistatin Explained

Blebbistatin is a myosin inhibitor mostly specific for myosin II.[1] [2] It is widely used in research to inhibit heart muscle myosin, non-muscle myosin II, and skeletal muscle myosin. Blebbistatin has been especially useful in optical mapping of the heart,[3] and its recent use in cardiac muscle cell cultures has improved cell survival time.[4] [5] However, its adverse characteristics e.g. its cytotoxicity and blue-light instability or low solubility in water often make its application challenging.[6] Recently its applicability was improved by chemical design and its derivatives overcome the limitations of blebbistatin.[7] E.g. para-nitroblebbistatin and para-aminoblebbistatin are photostable, and they are neither cytotoxic nor fluorescent.[8] [9]

Mode of action and biological effects

Blebbistatin inhibits myosin ATPase activity and this way acto-myosin based motility. It binds halfway between the nucleotide binding pocket and the actin binding cleft of myosin, predominantly in an actin detached conformation.[10] This type of inhibition relaxes the acto-myosin myofilaments and leads to several biological effects.

Blebbistatin inhibits the formation of blebs in melanoma cell culture,[11] hence its name. At a cellular level, blebbistatin also inhibits cytokinesis and may also disrupt mitotic spindle formation.[12] Migration of cells can be either enhanced or inhibited depending on other conditions.[13] In neurons, blebbistatin was found to promote neurite outgrowth.[14] At the organ level blebbistatin stops the contraction of skeletal muscle[15] or heart muscle.[16] Blebbistatin has also been found to stabilize the super relaxed state in the myofilaments, where myosin heads are in a helical order and interact with each other but not with actin.[17] [18] [19]

Adverse characteristics

A number of physicochemical deficiencies hamper the use of blebbistatin as a chemical tool in particular applications.

Photo-instability

Upon blue light illumination, blebbistatin becomes inactive and phototoxic due to changes in the structure of the compound accompanied by the generation of ROS [20] [6] [21]

Fluorescence

Blebbistatin is a relatively strong fluorophore. When dissolved in water, it absorbs at 420 nm and emits at 490 nm however in DMSO or when perfused through cardiac tissue, it absorbs around 430 nm and emits around 560 nm,[22] therefore at high concentrations its fluorescence interferes with GFP imaging or FRET experiments. Reduction of the concentration of blebbistatin to 6.25 uM allows for FRET imaging in isolated adult mouse cardiac muscle cells.

Cytotoxicity

Long-term incubation with blebbistatin results in cell damage and cytotoxicity, which are independent of the myosin inhibitory effect.

This photo-instability, phototoxicity and fluorescence makes in-vivo imaging of blebbistatin-treated samples impossible.

Myosin specificity

Blebbistatin is a potent inhibitor of nonmuscle myosin IIA and IIB, cardiac myosin, skeletal myosin and smooth muscle but does not inhibit myosin I, V and X.[23] [24] [25] The table below summarizes IC50 data of blebbistatin on different myosin isoforms.

speciesmyosin isoform or muscle typeassay typeIC50
myosin II motor domain basal ATPase2.96 ± 0.45 μM, 4.4 ± 0.3 μM, 4.9 μM
Dictyostelium discoideummyosin II motor domain actin activated ATPase3.9 ± 0.3 μM
Rabbit skeletal muscle II basal ATPase0.50 μM, 0.3 ± 0.03 μM, 0.41 ± 0.03 μM
Rabbit skeletal muscle II actin activated ATPase0.11 ± 0.009 μM
Porcineb-cardiac musclebasal ATPase1.2 μM
Scallopstriated musclebasal ATPase2.3 μM
Human nonmuscle IIAbasal ATPase5.1 μM
Chicken nonmuscle IIBbasal ATPase1.8 μM
Humannonmuscle IIAactin activated ATPase3.58 μM[26]
Humannonmuscle IIBactin activated ATPase2.30 μM
Mousenonmuscle IICactin activated ATPase1.57 μM
Turkey smooth musclebasal ATPase79.6 μM
Acanthamoebamyosin IIbasal ATPase83 μM
Rat myosin 1Bbasal ATPase>150 μM
Acanthamoebamyosin ICbasal ATPase>150 μM
Mouse myosin Vbasal ATPase>150 μM
Bovine myosin Xbasal ATPase>150 μM
smooth muscle myosin IIA heavy-chain actin activated ATPase3 μM
smooth muscle myosin IIB heavy-chain actin activated ATPase3 μM
Rabbit femoral, renal and saphenous artery tonic contraction5 μM
Chicken gizzardcontraction 20 μM
Chickengizzard smooth muscle HMMbasal ATPase15 ± 0.6 μM[27]
Chickengizzard smooth muscleactin activated ATPase6.47 μM
Ratbladdercontraction100% inhibition at 15 μM[28]
Mouseintact paced cardiac papillary muscle contraction1.3 μM[29]
Mouse Ca2+-activated, permeabilized cardiac papillary muscle contraction2.8 μM
Ratskinned cardiac trabeculaeCa2+ activated force0.38 ± 0.03 μM
Ratnative demembranated right ventricular trabeculaeisometric force development 3.17 ± 0.43 μM[30]
Drosophilanonmuscle myosin-2 actin activated ATPaseno inhibition[31]
Drosophilanonmuscle myosin-2 M466I mutationactin activated ATPase36.3 ± 4.1 μM
Drosophilacardiac tubesheart wall motion100 μM resulted in full inhibition[32]
Starfishnonmuscle myosin-2oocyte cytokinesiseffective at 300 μM[33]
C. elegansnonmuscle myosin-2acto-myosin colocalization microscopyeffective at 100 μM [34]
C. elegansnonmuscle myosin-2ventral enclosureeffective at 100 μM[35]
Podocoryna carnea (cnidarian)nonmuscle myosin-2stolon tip pulsations and gastrovascular floweffective at 255 μM[36]

Derivatives

The main aims of the structure-activity relationship work on the blebbistatin scaffold are the improvement of the physicochemical properties and the ATPase inhibitory potency, for use as chemical or pharmacological tools. Several analogs with superior properties have been developed, and guidelines for their optimal use have been described.

para-Nitroblebbistatin

See main article: Para-nitroblebbistatin. A non-fluorescent, non-phototoxic, non-cytotoxic derivative developed in 2014. Its myosin inhibitory properties are similar to those of blebbistatin (for rabbit skeletal muscle myosin S1 IC50=0.4 μM, for Dictyostelium discoideum myosin II motor domain IC50=2.3 μM, for human β-cardiac myosin subfragment 1 IC50=13 μM,[37] for heavy meromyosin fragment of chicken skeletal muscle myosin IC50=0.4 μM). It has been successfully used in fluorescent imaging experiments involving myosin IIA-GFP expressing live dendritic cells[38]

para-Aminoblebbistatin

See main article: para-Aminoblebbistatin. A water-soluble blebbistatin derivative developed in 2016, its high water solubility (~400 uM) enables in vivo research applications. Para-aminoblebbistatin is a slightly weaker myosin inhibitor than blebbistatin (for rabbit skeletal muscle myosin S1 IC50=1.3 μM, for Dictyostelium discoideum myosin II motor domain IC50=6.6 μM with only 90% maximal inhibition), it is non-fluorescent, photostable, neither cytotoxic nor phototoxic.

Azidoblebbistatin

A photoreactive myosin inhibitor developed in 2012.[39] A permanent inhibition of myosin may be achieved by covalently crosslinking the inhibitor azidoblebbistatin to its target by photoaffinity labeling (PAL). Briefly, upon UV illumination, the aryl-azide moiety in azidoblebbistatin forms a reactive nitrene.[40] This reaction is utilized to form covalent link between the inhibitor and myosin.

Azidoblebbistatin is also sensitive to two-photon irradiation, i.e. the covalent crosslink may also be generated by two-photon excitation microscope, therefore azidoblebbistatin is suitable for molecular tattooing.[41]

(S)-Nitroblebbistatin

This derivative was developed in 2005 to increase the photostability and decrease the fluorescence of blebbistatin.[42] (S)-nitro-blebbistatin is indeed stable to prolonged irradiation at 450-490 nm and has been successfully used in fluorescent live cell imaging.[43] However its affinity to myosin significantly decreased with the nitro-substitution (for nonmuscle myosin IIA, the IC50 = 27 μM). In many cases due to the low solubility, it is not possible to achieve full inhibition of myosin with (S)-nitro-blebbistatin. It is effective for FRET imaging of isolated adult mouse cardiac muscle cells.

(+)-Blebbistatin

(+)-Blebbistatin (or (R)-blebbistatin) is the inactive enantiomer of blebbistatin which inhibits the ATPase activity by maximum 10%.[44] In research, it is useful compound for control treatment, to check the non-myosin related toxic effects of blebbistatin.

Other derivatives

The blebbistatin scaffold has been modified in several ways to optimize myosin isoform specificity or to improve the inhibitory properties and to map the structure-activity relationship. Major steps in the optimization include the work of Lucas-Lopez et al. from 2008[45] and the works of Verhasselt et al. from 2017.[46] [47] [48] [49] The latter studies also include modifications of the A- and C-rings of the scaffold.

para-Chloroblebbistatin

A photostable, non-fluorescent, phototoxic derivative. Its fluorescence is less than 1% of that of blebbistatin myosin inhibitory properties are similar to those of blebbistatin. It is even more phototoxic than blebbistatin.

Notes and References

  1. Straight AF, Cheung A, Limouze J, Chen I, Westwood NJ, Sellers JR, Mitchison TJ . Dissecting temporal and spatial control of cytokinesis with a myosin II Inhibitor . Science . 299 . 5613 . 1743–7 . March 2003 . 12637748 . 10.1126/science.1081412 . 2003Sci...299.1743S . 38625401 .
  2. Roman BI, Verhasselt S, Stevens CV . Medicinal Chemistry and Use of Myosin II Inhibitor (S)-Blebbistatin and Its Derivatives . Journal of Medicinal Chemistry . 61 . 21 . 9410–9428 . June 2018 . 29878759 . 10.1021/acs.jmedchem.8b00503 .
  3. Swift LM, Asfour H, Posnack NG, Arutunyan A, Kay MW, Sarvazyan N . Properties of blebbistatin for cardiac optical mapping and other imaging applications . Pflügers Archiv . 464 . 5 . 503–12 . November 2012 . 22990759 . 3586237 . 10.1007/s00424-012-1147-2 .
  4. Kabaeva Z, Zhao M, Michele DE . Blebbistatin extends culture life of adult mouse cardiac myocytes and allows efficient and stable transgene expression . American Journal of Physiology. Heart and Circulatory Physiology . 294 . 4 . H1667–74 . April 2008 . 18296569 . 10.1152/ajpheart.01144.2007 .
  5. Reddy. Gopireddy Raghavender . West . Toni M. . Jian . Zhong . Jaradeh . Mark . Shi . Qian . Wang . Ying . Chen-Izu . Ye . Xian g. Yang K. . vanc . 2018-09-21. Illuminating cell signaling with genetically encoded FRET biosensors in adult mouse cardiomyocytes . The Journal of General Physiology. 150 . 11 . en. 1567–1582. 10.1085/jgp.201812119 . 30242036 . 6219686 .
  6. Kolega J . Phototoxicity and photoinactivation of blebbistatin in UV and visible light . Biochemical and Biophysical Research Communications . 320 . 3 . 1020–5 . July 2004 . 15240150 . 10.1016/j.bbrc.2004.06.045 .
  7. Rauscher AÁ, Gyimesi M, Kovács M, Málnási-Csizmadia A . Targeting Myosin by Blebbistatin Derivatives: Optimization and Pharmacological Potential . Trends in Biochemical Sciences . 43 . 9 . 700–713 . September 2018 . 30057142 . 10.1016/j.tibs.2018.06.006 .
  8. Képiró M, Várkuti BH, Végner L, Vörös G, Hegyi G, Varga M, Málnási-Csizmadia A . para-Nitroblebbistatin, the non-cytotoxic and photostable myosin II inhibitor . Angewandte Chemie . 53 . 31 . 8211–5 . July 2014 . 24954740 . 10.1002/anie.201403540 .
  9. Várkuti BH, Képiró M, Horváth IÁ, Végner L, Ráti S, Zsigmond Á, Hegyi G, Lenkei Z, Varga M, Málnási-Csizmadia A . A highly soluble, non-phototoxic, non-fluorescent blebbistatin derivative . Scientific Reports . 6 . 26141 . May 2016 . 27241904 . 4886532 . 10.1038/srep26141 . 2016NatSR...626141V .
  10. Kovács M, Tóth J, Hetényi C, Málnási-Csizmadia A, Sellers JR . Mechanism of blebbistatin inhibition of myosin II . The Journal of Biological Chemistry . 279 . 34 . 35557–63 . August 2004 . 15205456 . 10.1074/jbc.M405319200 . free . 10831/92817 . free .
  11. Cheung A, Dantzig JA, Hollingworth S, Baylor SM, Goldman YE, Mitchison TJ, Straight AF . A small-molecule inhibitor of skeletal muscle myosin II . Nature Cell Biology . 4 . 1 . 83–8 . January 2002 . 11744924 . 10.1038/ncb734 . 32475661 .
  12. Rosenblatt J, Cramer LP, Baum B, McGee KM . Myosin II-dependent cortical movement is required for centrosome separation and positioning during mitotic spindle assembly . Cell . 117 . 3 . 361–72 . April 2004 . 15109496 . 10.1016/s0092-8674(04)00341-1 . free .
  13. Kamimura M, Scheideler O, Shimizu Y, Yamamoto S, Yamaguchi K, Nakanishi J . 22216223 . Facile preparation of a photoactivatable surface on a 96-well plate: a versatile and multiplex cell migration assay platform . Physical Chemistry Chemical Physics . 17 . 21 . 14159–67 . June 2015 . 25959431 . 10.1039/c5cp01499a . 2015PCCP...1714159K .
  14. Yu P, Santiago LY, Katagiri Y, Geller HM . Myosin II activity regulates neurite outgrowth and guidance in response to chondroitin sulfate proteoglycans . Journal of Neurochemistry . 120 . 6 . 1117–28 . March 2012 . 22191382 . 3296867 . 10.1111/j.1471-4159.2011.07638.x .
  15. Farman GP, Tachampa K, Mateja R, Cazorla O, Lacampagne A, de Tombe PP . Blebbistatin: use as inhibitor of muscle contraction . Pflügers Archiv . 455 . 6 . 995–1005 . March 2008 . 17994251 . 10.1007/s00424-007-0375-3 . 20503064 .
  16. Fedorov VV, Lozinsky IT, Sosunov EA, Anyukhovsky EP, Rosen MR, Balke CW, Efimov IR . Application of blebbistatin as an excitation-contraction uncoupler for electrophysiologic study of rat and rabbit hearts . Heart Rhythm . 4 . 5 . 619–26 . May 2007 . 17467631 . 10.1016/j.hrthm.2006.12.047 .
  17. Zhao FQ, Padrón R, Craig R . Blebbistatin stabilizes the helical order of myosin filaments by promoting the switch 2 closed state . Biophysical Journal . 95 . 7 . 3322–9 . October 2008 . 18599626 . 2547462 . 10.1529/biophysj.108.137067 . 2008BpJ....95.3322Z .
  18. Xu S, White HD, Offer GW, Yu LC . Stabilization of helical order in the thick filaments by blebbistatin: further evidence of coexisting multiple conformations of myosin . Biophysical Journal . 96 . 9 . 3673–81 . May 2009 . 19413972 . 2711421 . 10.1016/j.bpj.2009.01.049 . 2009BpJ....96.3673X .
  19. Wilson C, Naber N, Pate E, Cooke R . The myosin inhibitor blebbistatin stabilizes the super-relaxed state in skeletal muscle . Biophysical Journal . 107 . 7 . 1637–46 . October 2014 . 25296316 . 4190596 . 10.1016/j.bpj.2014.07.075 . 2014BpJ...107.1637W .
  20. Sakamoto T, Limouze J, Combs CA, Straight AF, Sellers JR . Blebbistatin, a myosin II inhibitor, is photoinactivated by blue light . Biochemistry . 44 . 2 . 584–8 . January 2005 . 15641783 . 10.1021/bi0483357 .
  21. Mikulich A, Kavaliauskiene S, Juzenas P . Blebbistatin, a myosin inhibitor, is phototoxic to human cancer cells under exposure to blue light . Biochimica et Biophysica Acta (BBA) - General Subjects . 1820 . 7 . 870–7 . July 2012 . 22507270 . 10.1016/j.bbagen.2012.04.003 .
  22. Swift LM, Asfour H, Posnack NG, Arutunyan A, Kay MW, Sarvazyan N . Properties of blebbistatin for cardiac optical mapping and other imaging applications . Pflügers Archiv . 464 . 5 . 503–12 . November 2012 . 22990759 . 3586237 . 10.1007/s00424-012-1147-2 .
  23. Limouze J, Straight AF, Mitchison T, Sellers JR . Specificity of blebbistatin, an inhibitor of myosin II . Journal of Muscle Research and Cell Motility . 25 . 4–5 . 337–41 . 2004-01-01 . 15548862 . 10.1007/s10974-004-6060-7 . 22355306 .
  24. Eddinger TJ, Meer DP, Miner AS, Meehl J, Rovner AS, Ratz PH . Potent inhibition of arterial smooth muscle tonic contractions by the selective myosin II inhibitor, blebbistatin . The Journal of Pharmacology and Experimental Therapeutics . 320 . 2 . 865–70 . February 2007 . 17132816 . 10.1124/jpet.106.109363 . 28556955 .
  25. Yumoto M, Watanabe M . Blebbistatin, a myosin II inhibitor, suppresses Ca(2+)-induced and "sensitized"-contraction of skinned tracheal muscles from guinea pig . Journal of Smooth Muscle Research = Nihon Heikatsukin Gakkai Kikanshi . 49 . 89–98 . 2013 . 24662474 . 5137305 . 10.1540/jsmr.49.89 .
  26. Zhang HM, Ji HH, Ni T, Ma RN, Wang A, Li XD . Characterization of Blebbistatin Inhibition of Smooth Muscle Myosin and Nonmuscle Myosin-2 . Biochemistry . 56 . 32 . 4235–4243 . August 2017 . 28714309 . 10.1021/acs.biochem.7b00311 .
  27. Wang HH, Tanaka H, Qin X, Zhao T, Ye LH, Okagaki T, Katayama T, Nakamura A, Ishikawa R, Thatcher SE, Wright GL, Kohama K . 7063637 . Blebbistatin inhibits the chemotaxis of vascular smooth muscle cells by disrupting the myosin II-actin interaction . American Journal of Physiology. Heart and Circulatory Physiology . 294 . 5 . H2060–8 . May 2008 . 18296570 . 10.1152/ajpheart.00970.2007 .
  28. Zhang X, Seftel A, DiSanto ME . Blebbistain, a myosin II inhibitor, as a novel strategy to regulate detrusor contractility in a rat model of partial bladder outlet obstruction . PLOS ONE . 6 . 10 . e25958 . 2011-10-07 . 22016792 . 3189232 . 10.1371/journal.pone.0025958 . 2011PLoSO...625958Z . free .
  29. Dou Y, Arlock P, Arner A . Blebbistatin specifically inhibits actin-myosin interaction in mouse cardiac muscle . American Journal of Physiology. Cell Physiology . 293 . 3 . C1148–53 . September 2007 . 17615158 . 10.1152/ajpcell.00551.2006 .
  30. Kampourakis T, Zhang X, Sun YB, Irving M . Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament . The Journal of Physiology . 596 . 1 . 31–46 . January 2018 . 29052230 . 5746517 . 10.1113/jp275050 .
  31. Heissler SM, Chinthalapudi K, Sellers JR . Kinetic characterization of the sole nonmuscle myosin-2 from the model organism Drosophila melanogaster . FASEB Journal . 29 . 4 . 1456–66 . April 2015 . 25636739 . 4396609 . 10.1096/fj.14-266742 . free .
  32. Viswanathan MC, Kaushik G, Engler AJ, Lehman W, Cammarato A . A Drosophila melanogaster model of diastolic dysfunction and cardiomyopathy based on impaired troponin-T function . Circulation Research . 114 . 2 . e6–17 . January 2014 . 24221941 . 4526186 . 10.1161/CIRCRESAHA.114.302028 .
  33. Web site: The Molecular Mechanism of Surface Contraction Waves in the Starfish Oocyte. Bischof. Johanna. vanc . The Heidelberg Document Repository .
  34. Kachur TM, Audhya A, Pilgrim DB . UNC-45 is required for NMY-2 contractile function in early embryonic polarity establishment and germline cellularization in C. elegans . Developmental Biology . 314 . 2 . 287–99 . February 2008 . 18190904 . 10.1016/j.ydbio.2007.11.028 . free .
  35. Web site: Studying Ventral Enclosure during C. elegans Epidermal Morphogenesis. Wernike. Denise . vanc . Concordia University Spectrum Research Repository . 31 July 2018 .
  36. Connally N, Anderson CP, Bolton JE, Bolton EW, Buss LW . The Selective Myosin II Inhibitor Blebbistatin Reversibly Eliminates Gastrovascular Flow and Stolon Tip Pulsations in the Colonial Hydroid Podocoryna carnea . PLOS ONE . 10 . 11 . e0143564 . 2015-11-25 . 26605798 . 4659590 . 10.1371/journal.pone.0143564 . 2015PLoSO..1043564C . free .
  37. Tang W, Blair CA, Walton SD, Málnási-Csizmadia A, Campbell KS, Yengo CM . Modulating Beta-Cardiac Myosin Function at the Molecular and Tissue Levels . Frontiers in Physiology . 7 . 659 . 2017 . 28119616 . 5220080 . 10.3389/fphys.2016.00659 . free .
  38. Chabaud M, Heuzé ML, Bretou M, Vargas P, Maiuri P, Solanes P, Maurin M, Terriac E, Le Berre M, Lankar D, Piolot T, Adelstein RS, Zhang Y, Sixt M, Jacobelli J, Bénichou O, Voituriez R, Piel M, Lennon-Duménil AM . Cell migration and antigen capture are antagonistic processes coupled by myosin II in dendritic cells. . Nature Communications . 6 . 7526 . June 2015 . 26109323 . 4491822 . 10.1038/ncomms8526 . 2015NatCo...6.7526C .
  39. Képiró M, Várkuti BH, Bodor A, Hegyi G, Drahos L, Kovács M, Málnási-Csizmadia A . Azidoblebbistatin, a photoreactive myosin inhibitor . Proceedings of the National Academy of Sciences of the United States of America . 109 . 24 . 9402–7 . June 2012 . 22647605 . 3386077 . 10.1073/pnas.1202786109 . 2012PNAS..109.9402K . free .
  40. Web site: Photoreactive Crosslinker Chemistry. Thermo Fisher Scientific .
  41. Képiró M, Várkuti BH, Rauscher AA, Kellermayer MS, Varga M, Málnási-Csizmadia A . Molecular tattoo: subcellular confinement of drug effects . Chemistry & Biology . 22 . 4 . 548–558 . April 2015 . 25892202 . 10.1016/j.chembiol.2015.03.013 . free .
  42. Lucas-Lopez . Cristina . Patterson . Stephen . Blum . Till . Straight . Aaron F.. Toth. Judit. Slawin. Alexandra M. Z.. Mitchison. Timothy J.. Sellers. James R.. Westwood. Nicholas J. . vanc . 2005-05-01. Absolute Stereochemical Assignment and Fluorescence Tuning of the Small Molecule Tool, (–)-Blebbistatin . European Journal of Organic Chemistry. en. 2005. 9. 1736–1740. 10.1002/ejoc.200500103 .
  43. Ponsaerts R, D'hondt C, Bultynck G, Srinivas SP, Vereecke J, Himpens B . The myosin II ATPase inhibitor blebbistatin prevents thrombin-induced inhibition of intercellular calcium wave propagation in corneal endothelial cells . Investigative Ophthalmology & Visual Science . 49 . 11 . 4816–27 . November 2008 . 18614806 . 10.1167/iovs.07-1533 . free .
  44. Web site: Supportin information for the article "Absolute Stereochemical Assignment and Fluorescence Tuning of the Small Molecule Tool, (–)-Blebbistatin". Lucas-Lopez. Cristina . vanc .
  45. Lucas-Lopez C, Allingham JS, Lebl T, Lawson CP, Brenk R, Sellers JR, Rayment I, Westwood NJ . The small molecule tool (S)-(-)-blebbistatin: novel insights of relevance to myosin inhibitor design . Organic & Biomolecular Chemistry . 6 . 12 . 2076–84 . June 2008 . 18528569 . 3758137 . 10.1039/b801223g .
  46. Verhasselt S, Roman BI, De Wever O, Van Hecke K, Van Deun R, Bracke ME, Stevens CV . Discovery of (S)-3'-hydroxyblebbistatin and (S)-3'-aminoblebbistatin: polar myosin II inhibitors with superior research tool properties . Organic & Biomolecular Chemistry . 15 . 9 . 2104–2118 . March 2017 . 28220174 . 10.1039/c7ob00006e . 1854/LU-8514040 . free .
  47. Verhasselt S, Roman BI, Bracke ME, Stevens CV . Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs . European Journal of Medicinal Chemistry . 136 . 85–103 . August 2017 . 28486210 . 10.1016/j.ejmech.2017.04.072 . 1854/LU-8519711 . free .
  48. Verhasselt S, Stevens CV, Van den Broecke T, Bracke ME, Roman BI . Insights into the myosin II inhibitory potency of A-ring-modified (S)-blebbistatin analogs . Bioorganic & Medicinal Chemistry Letters . 27 . 13 . 2986–2989 . July 2017 . 28512027 . 10.1016/j.bmcl.2017.05.008 . 1854/LU-8519713 . free .
  49. Roman BI, Verhasselt S, Mangodt CW, De Wever O, Stevens CV . Synthesis of C-ring-modified blebbistatin derivatives and evaluation of their myosin II ATPase inhibitory potency . Bioorganic & Medicinal Chemistry Letters . 28 . 13 . 2261–2264 . July 2018 . 29807794 . 10.1016/j.bmcl.2018.05.041 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Blebbistatin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.